Happy to confirm: attendees receive 16 European CME credits Malta, 19-21 Nov 😊 Great faculty (@gurujosh.bsky.social @steventong.bsky.social David Paterson, others) Register www.escmid.org/event-detail... Organized by @clarityinitiative.bsky.social @cmicomms.bsky.social @escmid.bsky.social #IDSky

The OPTIMISE trial aimed to test 7 vs 14 days for treating MDR infections in ICU patients. Although underpowered due to early stop, no signal of inefficacy was observed for short treatments Pseudomonas were underrepresented in this trial 🙁 link.springer.com/article/10.1... #AMSsky #IDsky #PsWatch

Shorter is also better in ICU patients Timsit, Roberts, @angelahuttner.bsky.social, Daneman &c State-of-the-Art in AJRCCM @atsblueeditor.bsky.social For most ICU patients with (suspected) infections, abx can be 🛑 at 5-7d w clinical improvement academic.oup.com/ajrccm/advan... #IDSky #CritCareSky

I find cefepime very useful to diversify empiric antipseudomonal treatments among immunocompromised hosts, and as a carbapenem-sparing agent against ampC producers. This recent metaanalysis made me wonder if I should stop using it… 🧵(1/5) jamanetwork.com/journals/jam... #IDSky #AMSsky #IDOnc

Cefepime and Mortality

This systematic review with bayesian meta-analysis of randomized clinical trials examined the association of cefepime with all-cause mortality compared with other β-lactam antibiotics.

jamanetwork.com

Demystify clinical trial design & enhance your research toolkit!📊✨ Join our statistical seminars supported by @advance-id.bsky.social & @who.int Explore clinical trial theory & real-life examples with global experts. Master the numbers in the mission against disease here: ad-id.co/stats

Immunocompromised hosts should not be excluded from duration trials. The question is how we can safely incorporate them into these studies to generate the evidence we need. Our editorial in @cmijournal.bsky.social is freely available here: 🔓 authors.elsevier.com/a/1nOm-,RGPg... #IDsky #TxID #IDOnc

👏 Investigadoras @ibis-investigacion.bsky.social desarrollan una prueba rápida para detectar una bacteria resistente en sangre. 🔍La nueva herramienta permite identificar en pocas horas la bacteria Pseudomonas aeruginosa y uno de sus factores de virulencia más agresivos. [+]

For years, the need for longer durations in immunocompromised patients was treated as the exception to every shorter-duration bacteremia discussion. BALANCE may have finally put that belief to rest. Dogma continues to lose ground. #idsky

Antibiotic Steward 🅱️C🆔🅿️🌟@absteward.bsky.social · 4mo ago

🆕🔥🟢Post hoc subgroup analysis of the BALANCE RCT 7 Vs 14d duration of antibiotic therapy for bacteremia in immune compromised hosts 1037 immune compromised patients #idsky www.clinicalmicrobiologyandinfection.org/article/S119...

SHORTEN2 results have been presented at #CongresoSEIMC2026! 7-day treatments were shown superior to 14-day in reducing antibiotic exposure and adverse events while maintaining efficacy. Fantastic work by >100 researchers across 37 Spanish hospitals! #TeamPride #IDsky #AMSsky @seimc.bsky.social

Amazing 😍 🔥SHORTEN 2 RCT A 7-day treatment course is superior to 14 days for uncomplicated Pseudomonas aeruginosa bacteremia, achieving similar clinical response rates with lower antibiotic exposure, fewer superinfections, and fewer serious adverse events #idsky @shorten2trial.bsky.social

We’re happy to share that results of the @shorten2trial.bsky.social will be presented at the #XXIXCongresoSEIMC! 📆 Friday, May 29 - 14:25h 📍Room 0D 📻 Stay tuned! #AMSsky #IDSky @absteward.bsky.social @idstewardship.bsky.social @bradspellberg.bsky.social @drtoddlee.bsky.social @esgap.bsky.social

What's in a name? Pseudomonas aeruginosa—from Sédillot’s blue-green wound dressings and grapes like odor (1850), to Gessard’s isolation (1882), to Migula’s formal naming of the genus (1900). A pathogen that made its name unforgettable recognizable #IDsky

ESCMID 2026 highlights COBRA Trial – One day is enough Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days. Bottom line: Antibiotic durations can safely be much shorter once source control is achieved. #IDSky clarityinitiative.org/escmid-2026-...

Clarity Initiative

Clinical Literature Appraisal and Research education in InfecTious diseases

clarityinitiative.org

Can we use short treatments for bacteremia in #SOT? This metaanalysis of observational data + SOT randomized in prior trials suggests the efficacy of short courses. We’ve got the rationale to stop excluding SOT from duration trials! onlinelibrary.wiley.com/doi/10.1111/... #IDSky #AMSsky #TxID

Outcomes of Short Antibiotic Courses for Gram‐Negative Bloodstream Infections in Solid Organ Transplant Recipients—A Systematic Review and Meta‐Analysis

In this meta-analysis of seven studies involving 249 solid organ transplant (SOT) recipients with Gram-negative bloodstream infections, no statistically significant differences in mortality or clinic....

onlinelibrary.wiley.com

We’re happy to share that results of the @shorten2trial.bsky.social will be presented at the #XXIXCongresoSEIMC! 📆 Friday, May 29 - 14:25h 📍Room 0D 📻 Stay tuned! #AMSsky #IDSky @absteward.bsky.social @idstewardship.bsky.social @bradspellberg.bsky.social @drtoddlee.bsky.social @esgap.bsky.social

🔥 💥Late-Breakers |COBRA RCT 1-day of antibiotic treatment after adequate endoscopic biliary drainage is non-inferior to 4-7 days in adults with acute cholangitis. 💡 Shorter is better+source control Practice-changing? #ESCMIDGlobal2026 #idsky

Combined antipseudomonal therapy does not improve outcomes and may increase toxicity. Its main role is ensuring appropriate empirical therapy in severe infections, with no proven benefit once susceptibility is known. 📖 A systematic review: www.tandfonline.com/doi/full/10.... #AMSsky #IDsky #PsWatch

This post hoc analysis of the subgroup of patients with P. aeruginosa BSI recruited for the BALANCE RCT showed no differences in 90d mortality between patients treated for 7 vs 14d. However, sample size and wide CIs preclude definite conclusions. academic.oup.com/cid/advance-... #IDsky #AMSsky

1st cefepime-zidebactam resistance in P. aeruginosa pneumonia🚨 MIC rose from 8/8 to 32/32 mg/L⚠️ New MexAB-OprM mutations caused cross-resistance🔄 to ceftazidime-avibactam & imipenem-relebactam.

Recruitment for SHORTEN-2 is officially complete! Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026! Hats off to this awesome research team! 🥳 #AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social

Fantastic - this will be an impactful study on treatment duration of blood stream Pseudomonas infection. Our centre already mostly does 7 days (and my prediction is that this will be non-inferior) but it's RCT like these that will shift dial across the board with persuasive evidence. #IDSky #AMR

SHORTEN-2 trial@shorten2trial.bsky.social · 12mo ago

Recruitment for SHORTEN-2 is officially complete! Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026! Hats off to this awesome research team! 🥳 #AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social

Recruitment for SHORTEN-2 is officially complete! Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026! Hats off to this awesome research team! 🥳 #AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social

It’s encouraging to see new guidelines moving toward shorter and fully-oral treatments for BSIs. We are honoured to see some of our research cited to help shape these recommendations! 😃 #AMSsky #IDsky #UTIsky @hospitaluvrocio.bsky.social @ibis-investigacion.bsky.social bsky.app/profile/jose...

José Molina@josemolinagb.bsky.social · 2y ago

Can we treat patients with low-risk BSI discharged from the ED with a fully-oral course of antibiotics? [Spoiler: Yes!] 🆓🔓Our recent article on #OralIsTheNewIV! 👉🏻 journals.asm.org/doi/10.1128/... Food for thought for #AMSsky #IDSky

This metaanalysis of observational studies in SOT suggests that non-complicated graft infections could be treated 7d, and yet transplant patients have been excluded from most RCT on duration. Time for a #ShorterIsBetter RCT in #TxID! kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F... #IDsky #AMSsky

José Molina@josemolinagb.bsky.social · last yr.

Do AMS really work in transplant units and what is yet to be done? Happy to share our systematic review in @eclinicalmed.bsky.social which we hope will support AB stewardship implementation in SOT units and future research steps #AMSsky #TxID #IDsky kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...

Check out this cool collaboration with @hernando-amado.bsky.social, just out in @natcomms.nature.com! We show that ciprofloxacin resistance rapidly declines in clinical P. aeruginosa strains under drug-free conditions, suggesting that ciprofloxacin restriction periods could help in clinics 🦠🧫

Sara Hernando-Amado@hernando-amado.bsky.social · last yr.

I am very happy to share our latest study on ciprofloxacin resistance instability in P. aeruginosa during periods of drug restriction. A fantastic collaboration @pablolaborda.bsky.social, RuggeroLaRosa, JLMartínez, SørenMolin & HelleJohansen 🥳 @cnb-csic.bsky.social www.nature.com/articles/s41...

Variability in Durations of Therapy for Gram-Negative Bloodstream Infections and Factors Associated with Prolonged Durations ✅ Just Accepted ⭐ Editor's Choice #IDSky

Variability in Durations of Therapy for Gram-Negative Bloodstream Infections and Factors Associated with Prolonged Durations

In this study of 4,240 GN-BSI episodes during 2019 from 24 U.S. hospitals, the median duration of therapy was 12 days (IQR 9-15); 59% were treated for >10 days. There was marked variability in treatment durations across hospitals.

doi.org

Today we celebrated our 3rd Annual Researchers’ Meeting at the XXVIII Congress of @seimc.bsky.social! Only 2️⃣4️⃣ patients left to complete the trial! An amazing team doing an amazing work! 🤩🔝 #IDSky #AMSsky #TeamPride

Sociodemographic features have a strong influence on antibiotic use, and yet antimicrobial stewardship trials showed the lowest reporting rates of these data among RCTs in this systematic review. Fantastic work @seanong.bsky.social! An important heads-up for #AMSsky #IDsky researchers 💪🏼

Sean Ong@seanong.bsky.social · last yr.

Our new paper in @cmijournal.bsky.social, a systematic review where we evaluated reporting of baseline sociodemographic characteristics across 1343 ID clinical trials over a 10-year period. A 🧵: @steventong.bsky.social #IDSky doi.org/10.1016/j.cm...

Caring for patients with bronchiectasis poses a challenge for both pulmonologists and #AMSky teams. Standard 14d treatments for exacerbations lack good evidence support. This small RCT favors shorter durations such as 8d 👉🏻 publications.ersnet.org/content/erj/... #IDsky @bradspellberg.bsky.social

Miranda So PharmD MPH (Epidemiology)@mirandapharmdmph.bsky.social · last yr.

Excellent review in @jama.com on non-CF bronchiectasis in adults. Appreciate the authors delineating on the role played by infections and the role played by antibiotics. jamanetwork.com/journals/jam...

Fascinating and important study. May well be transformative in treatment of stubborn chronic lung infections such as by Pseudomonas aeruginosa in #cysticfibrosis and beyond rdcu.be/ekdWf

Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis

Nature Medicine - A novel personalized phage therapy strategy that selects phages for a predicted evolutionary trade-off may represent a viable alternative approach for the treatment of...

rdcu.be